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 Benzodiazepine prescribing is higher in practices with underserved populations 
 This association is seen more strongly in certain drugs of this class 







Benzodiazepines and Z-drugs (such as zopiclone) are widely prescribed in primary care. Given their 
association with addiction and dependence, understanding where and for whom these medications 
are being prescribed is a necessary step in addressing potentially harmful prescribing.  
Objective 
To determine whether there is an association between primary care practice benzodiazepine and Z-
drug prescribing and practice population socioeconomic status in England. 
Methods 
This was a cross-sectional study. An aggregated dataset was created to include primary care 
prescribing data for 2017, practice age and sex profiles, and practice Index of Multiple Deprivation 
(IMD) scores – a marker of socioeconomic status. Drug doses were converted to their milligram-
equivalent of diazepam to allow comparison. Multiple linear regression was used to examine the 
association between IMD and prescribing (for all benzodiazepines and Z-drugs in total, and 
individually), adjusting for practice sex (% male) and older age distribution (% >65s).  
Results 
Benzodiazepine and Z-drug prescribing overall was positively associated with practice-level IMD score, 
with more prescribing in practices with more underserved patients, after adjusting for age and sex 
(p<0.001), although the strength of the association varied by individual drug. Overall, however, IMD 







Our findings may, in part, be a reflection of an underlying association between the indications for 
benzodiazepine and Z-drug prescribing and socioeconomic status. Further work is required to more 
accurately define the major contributors of prescribing variation. 
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Benzodiazepines and Z-drugs are classes of medication with similar pharmacological mechanisms of 
action, both being functional at GABAA receptors. Benzodiazepines are used for a wide range of 
indications and durations, with different drugs within the class being more suited to different 
situations (such as chlordiazepoxide for alcohol withdrawal, and clobazam for epilepsy). In primary 
care, common indications for use include insomnia, anxiety and acute back pain. Benzodiazepines 
have been in common use since the 1960s, when they were initially thought to be less addictive and 
safer than alternatives in the treatment of anxiety and insomnia1. It is now appreciated that 
benzodiazepines have a high risk of dependency and withdrawal symptoms even at normal doses2. 
Indeed, they are thought to be at least as addictive as opiates, and the duration of withdrawal may be 
longer3. Z-drugs are a group of non-benzodiazepine medications, the most well-known of which is 
zopiclone, which are frequently prescribed for insomnia. Whilst this class of medications were 
reportedly considered safer than benzodiazepines4, long-term Z-drug use is also associated with 
tolerance and dependence5,6. This poses difficult questions regarding the management of dependency 
and withdrawal, which have frequently been cited as a national priority in the UK and USA7. 
Around 300,000 people in the UK are on long-term prescriptions for benzodiazepines8, and zopiclone 
prescription rates continue to increase, particularly in the elderly population4. Significant medical and 
social concerns arise from use of these medications long-term: benzodiazepines have been associated 
with an increased risk of falls causing significant injury9, traffic accidents10, cognitive impairment11 and 
dementia12. These effects may be especially marked in the elderly13. There is also a significant market 
in illicit benzodiazepine and Z-drug sale and use14.  
In light of a landmark review currently being undertaken by Public Health England into prescription 
drugs likely to lead to dependence and withdrawal15, it has never been more important for us to 
understand the geographic and demographic distribution of prescriptions in primary care. In the UK 
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and the USA, benzodiazepines and Z-drugs are more commonly prescribed in the elderly population 
and in females16,17. A study conducted in 2004/5 suggested that practice-level benzodiazepine 
prescribing may be related to socioeconomic status, as defined by Index of Multiple Deprivation (IMD) 
scores18. However, this study did not consider Z-drugs, and only looked at benzodiazepine prescribing 
as a whole. It may be that some benzodiazepines, but not others, are driving the apparent overall 
association with low socioeconomic status. Furthermore, the proportion of patients being prescribed 
benzodiazepines has gradually declined since this time19. This may reflect a shift in prescribing habits.  
Here, we use recent primary care prescribing data from England to explore associations between 
primary care practice-level benzodiazepine and Z-drug prescribing and socioeconomic status (SES). 





This is a cross-sectional study of monthly prescribing data for primary care practices in England in 
2017, which were downloaded from NHS Digital (https://digital.nhs.uk)20. This gives information for 
each GP practice and their Clinical Commissioning Group (CCG – regional bodies that are responsible 
for planning and commissioning healthcare services for their local area), and for each drug 
preparation: (1) the number of items prescribed that month; and (2) the total quantity prescribed that 
month (i.e. number of tablets or total in milligrams if the preparation is a liquid). The total quantity 
prescribed was chosen as the primary outcome measure, rather than the number of items, as it gives 
a more accurate picture of how much of each drug was prescribed. Private prescriptions are not 
recorded in these datasets. Information on GP practice list sizes (from January 2017), including 
stratification by sex and 5-year age bands, was also retrieved from NHS Digital21, as were British 
National Formulary (BNF) drug codes22. BNF codes are unique for each drug preparation; for example, 
the codes for diazepam 5mg tablets, diazepam 10mg tablets, and diazepam 10mg/ml in oral solution 
are all different. 
Information about the equivalence of benzodiazepines and Z-drugs is published in the BNF23. It gives, 
for each drug, the approximate dose which is equivalent to 5mg of diazepam, thus allowing 
comparisons to be made across the different drugs in these classes. The equivalences used are given 
in Supplementary Material 1. 
Data on practice-level and CCG-level socioeconomic status were obtained from Public Health 
England’s National General Practice Profiles24. Socioeconomic status was quantified using the Index of 
Multiple Deprivation (IMD) score from 2015. The IMD score combines information from seven 
domains to produce an overall relative measure of SES. The domains are combined using the following 
weights25: income deprivation (22.5%); employment deprivation (22.5%); education, skills and training 
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deprivation (13.5%); health deprivation and disability (13.5%); crime (9.3%); barriers to housing and 
services (9.3%); and living environment deprivation (9.3%).  
 
Data Processing  
Primary care prescribing data for each month in 2017 were aggregated by BNF drug code to give the 
total number of items and total quantity prescribed under each BNF code per practice over a year. 
Practices with fewer than 1000 patients were excluded. All oral formulations (tablet and solution) of 
benzodiazepine and Z-drugs were included. In order to standardise the quantities of different drugs 
prescribed, all drug doses were converted into their milligram-equivalent of diazepam. The total 
prescribed quantities (in mg-equivalent of diazepam) were then aggregated, by practice, for each drug 
irrespective of the initial preparation. Information on the following were added to the aggregated 
prescribing dataset: practice-level IMD score, total list size, the proportion of males in the practice list, 
and the proportion of over-65s (calculated from the age-stratified practice list size dataset). 
Prescribing in each practice was then calculated in milligram equivalents of diazepam per 1000 
patients.  
Practice-level prescribing is presented by IMD decile, showing the mean and 95% confidence interval 
(CI), where decile ten represents the practices with the highest IMD score. To process the data for 
presentation on a regional map by CCG, the same process was followed as above, but aggregating 
prescribing and list sizes by CCG rather than by practice. NHS Manchester CCG was formed in April 
2017 as a merger of three separate CCGs (North, Central and South Manchester CCGs). For this case, 
all data from the three superseded CCGs (i.e. prior to April 2017) were recoded as being from NHS 
Manchester CCG. Prescribing was then stratified by decile and plotted on choropleth maps of England, 
using CCG boundary shapefiles published by the Office for National Statistics (ONS)26. The same was 
done for CCG-level IMD scores. In order to display both IMD decile and prescribing level on a single 
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CCG map, bivariate choropleth maps were created by splitting each variable into tertiles and plotting 
each variable in a different colour. 
The individual drugs studied included those which constituted more than 0.1% of items of 
benzodiazepines or Z-drugs prescribed across 2017. These were: chlordiazepoxide, clobazam, 
clonazepam, diazepam, lorazepam, nitrazepam, oxazepam, temazepam and zopiclone. Bromazepam 
and zaleplon (both < 0.01% of items) were excluded.  
 
Statistical Analysis  
The association between practice-level IMD score and benzodiazepine prescribing quantity per 1000 
patients was testing using simple (univariate) linear regression. The assumptions of linear regression 
were satisfied, except that of a normal distribution of residuals. However, linear regression can still be 
appropriate in the absence of non-normally distributed residuals where the sample size is large, as in 
this study27.  Multivariable linear regression was conducted using both the practice proportion of 
males and the proportion of over-65s as independent variables, to test whether practice-level IMD 
was associated with prescribing independently of practice age and sex distribution. The results of 
linear regression analyses are presented as unstandardized coefficients of regression (), which 
denote the extra amount of mg-equivalent diazepam prescribed per 1000 patients for each one-point 
increase in practice IMD score, and adjusted R2 values (the proportion of the variability in prescribing 
that is explained by the factors studied in the regression model). A p value < 0.05 is considered 
statistically significant. All data were analysed, and all plots generated, using the software R7. As all 




Association between socioeconomic status and total benzodiazepine and Z-drug prescribing 
In 2017, over 14.6 million prescriptions of benzodiazepines and Z-drugs were written in England, 
totalling more than the equivalent of 2.3 billion milligrams of diazepam. Over a third of the items 
prescribed were for diazepam, with a similar proportion being for zopiclone (Figure 1).  
The association between total benzodiazepine and Z-drug prescribing and practice IMD score decile 
was examined (Figure 2). This shows that prescribing was statistically significantly higher in decile 10 
(the highest IMD scoring practices) compared to the lowest decile. Specifically, practices in the lowest 
IMD decile prescribed fewer benzodiazepines that those in every other decile. 
On univariate analysis, there was a significant association between practice IMD score and prescribing 
(= 164 [95% CI 119-209], p < 0.001). After accounting for sex distribution and the proportion of over-
65s, this association was strengthened ( = 628 [95% CI 580-676)], p < 0.001). The combination of the 
three variables practice IMD score, proportion of males and proportion of over-65s explained almost 
a fifth of the variability in total benzodiazepine and Z-drug prescribing across practices (multiple R2 = 
18%). 
 
Association between socioeconomic status and prescribing for individual drugs 
In univariate analyses, all drugs except zopiclone were statistically significantly associated with 
practice IMD score. Once age and sex were taken into account in the multivariable model, IMD score 
was significantly associated with prescribing levels for all individual drugs, with more prescribing seen 
in practices with higher IMD scores. The combination of practice IMD score, age and sex accounted 
for between 6% and 13% of the variation seen in prescribing of individual drugs, leaving a significant 
proportion of the variation unaccounted for. A summary of the results of univariate and multiple linear 
11 
 
regression tests for the association between the level of prescribing for each individual drug and 
practice IMD score is shown in Table 1. The varying strengths of association between prescribing and 
SES is unsurprising given that individual benzodiazepines are favoured for different indications. The 
strongest associations were seen with nitrazepam and clobazam (see Supplementary Material 2, 
which includes relevant plots for all individual drugs). 
 
Geographical Variation in Prescribing  
Choropleth maps showing deciles of prescribing rates by CCG for total benzodiazepine and Z-drug 
prescribing are shown in Figure 3 (see Supplementary Material 2 for a choropleth map of regional CCG 
IMD deciles). Rates of benzodiazepine prescribing are highest in the East of England, as well as in 
dispersed coastal regions around the UK. Interestingly, CCGs with the highest prescribing rates do not 
necessarily coincide with those with the highest IMD scores. Similarly, there is no clear north/south 
divide in CCG-level benzodiazepine and Z-drug prescribing. 
In order to simultaneously display CCG-level prescribing and socioeconomic status, and to visualise 
any correlations, a bivariate choropleth map was created (Figure 4). This visualisation suggests that, 
at the CCG level, coastal areas tend to have lower IMD scores but more prescribing. Indeed, very few 
CCGs have both high IMD scores and high prescribing. The finding of higher prescribing in coastal 
regions warrants further study, but it is notable that coastal regions also tend to have a higher 




In this study, we examined the association between benzodiazepine and Z-drug prescribing and 
socioeconomic status in England. We have found that practices with a higher IMD score tend to have 
higher prescription rates, after adjusting for age and sex, although these three factors alone only 
explain a relatively small percentage of the total variation in benzodiazepine and Z-drug prescribing. 
The prescription of benzodiazepines and Z-drugs is subject to large geographical variation in England; 
for example, we found a preponderance of higher prescribing rates in coastal regions, but no clear 
north-south divide. Social status alone cannot explain this geographic variation. The strength of the 
association between IMD scores and prescribing rates was not replicated for each individual drug, 
likely as an expression of the diverse indications for these medications. For example, chlordiazepoxide 
– used to manage alcohol withdrawal – showed unique geographical patterning, being prescribed at 
a relatively low rate in some relatively underserved areas. It may be that cultural influence is important 
in this case, as the Muslim population, who generally do not drink alcohol, are a sizeable proportion 
of some these regional subpopulations28,29. It is likely that the study of prescribing stratified by 
indication (e.g. anxiety) may help to improve the relevance of associations with SES. 
A recent study in Ireland analysing benzodiazepine and Z-drug prescribing in adults nationally found a 
third of patients receiving these drugs were on longer-term prescriptions (over 90 days), with 
prescribing rates highest in older women30. Whilst the association with age and sex is in line with our 
findings, and that of other studies31,32, the authors did not consider socioeconomic status. A Scottish 
population-based study of adults over the age of 65 years found that 12% were prescribed one or 
more benzodiazepine and Z-drug, although care-home residents were three-times as likely to be on 
this class of drugs16. This more convincingly highlights the impact of age as a predictor of prescription. 
A study examining the relationship between patient and practice factors and anxiolytic and hypnotic 
prescribing using data from 2004/5 in England also found a relationship with low socioeconomic 
status, as well as increased prescribing in practices with a lower proportion of ethnic minorities18. 
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Whilst we found that the relationship persists in 2017 with respect to benzodiazepine and Z-drug 
prescribing overall, we also demonstrated that the strength of the association differed between drugs 
within these classes. 
 
Strengths and Limitations 
We evaluated the prescribing of benzodiazepines and Z-drugs in primary care practices across 
England, thus removing selection bias. Aggregating data across a calendar year avoided the potential 
effects of seasonal variation. 
There are limitations to the presented study. IMD score is not a direct measure of socioeconomic 
status, and the IMD score attributed to a GP practice does not necessarily reflect the socioeconomic 
status of those patients who are prescribed benzodiazepines, so we cannot conclude that patients 
with a low socioeconomic status are more likely to be prescribed these medications.  A further 
limitation of aggregated data is the lack of detail around the intended indications for prescribing. We 
did not consider prescriptions originating outside of primary care or private prescriptions, and these 
may have had an impact on results; for example if those in underserved populations are less likely to 
seek private prescriptions. Finally, the effects of patient- and practice-level factors (other than age 
and sex) on prescribing were not included in our regression model. 
 
Implications for Research and Practice 
We found an association between primary care practice-level socioeconomic status and practice-level 
prescribing of benzodiazepines and Z-drugs in England in 2017, although the combination of IMD 
score, age and sex only explained a small proportion of the variation in prescribing. Whilst it is possible 
that similar associations may be seen in other settings and countries, this would require direct 
investigation. Further work is required on individual-level datasets from primary care to determine 
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which patient-level and practice-level factors are driving the prescription of these drugs, to help 
identify where future interventions to reduce prescribing should be targeted. Whilst Z-drugs and 
benzodiazepines are commonly prescribed and effective in specific situations, the side-effects and 
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Figure 1. The prescribing level for each drug, as a proportion of total benzodiazepine and Z-












Figure 2. Benzodiazepine and Z-drug prescription levels per 1000 registered patients by 
practice Index of Multiple Deprivation Deciles in England (2017). For Index of Multiple 
Deprivation (IMD) deciles, 1 is the lowest scores (most underserved) and 10 is the highest 











Figure 3: Benzodiazepine and Z-drug prescribing by region (by Clinical Commissioning Group 
in England, 2017). 
Geographical choropleth map of England, categorising Clinical Commissioning Group regions 
according to deciles of benzodiazepine and Z-drug prescribing. Decile 1 is the lowest level of 









Figure 4. Benzodiazepine and Z-drug prescribing and Index of Multiple Deprivation scores 
by region (by Clinical Commissioning Group in England, 2017).   
Bivariate choropleth map of England combining information on the rate of benzodiazepine 
and Z-drug prescribing and socioeconomic status as described by Index of Multiple 
Deprivation (IMD) scores (by tertiles). Where IMD scores and prescribing are in the same 
tertile, white or blue shading is given. Alternative shading represents either a higher tertile 
of IMD score than benzodiazepine prescribing (purple), or a higher tertile of prescribing than 




Table 1. Summary of linear regression results for each individual drug, and all drugs in 
total, of the association between practice Index of Multiple Deprivation (IMD) score and 
benzodiazepine and Z-drug prescribing levels in England (2017). coefficients are in mg-
equivalent diazepam per 1000 registered patients.  The multivariable model is adjusted for 
the proportion of males and the proportion of over-65s in each practice.  
        
Drug   Univariate  Multivariable 
All benzodiazepine &          
Z-drug prescriptions 
 164 628 
p value < 0.001 < 0.001 
adjusted R2 0.70% 18% 
        
    
Chlordiazepoxide 
 22 20 
p value < 0.001 0.003 
adjusted R2 6% 13% 
        
    
Clobazam 
 121 162 
p value < 0.001 < 0.001 
adjusted R2 8% 12% 
        
    
Clonazepam 
 79 146 
p value < 0.001 < 0.001 
adjusted R2 1% 6% 
        
    
Diazepam 
 73 164 
p value < 0.001 < 0.001 
adjusted R2 1% 7% 
        
    
Lorazepam 
 50 114 
p value < 0.001 < 0.001 
adjusted R2 1% 11% 
        
    
Nitrazepam 
 36 45 
p value < 0.001 < 0.001 
adjusted R2 6% 13% 
        
    
Temazepam 
 37 55 
p value < 0.001 < 0.001 
adjusted R2 2% 8% 
        
    
Zopiclone 
 4 83 
p value 0.47 < 0.001 
adjusted R2 <0.1% 13% 
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Supplementary Material 1 
 
Benzodiazepine and Z-drug equivalences 
From the BNF: https://bnf.nice.org.uk/treatment-summary/hypnotics-and-anxiolytics.html 
 
The following doses are approximately equivalent to 5mg of diazepam: 
 Alprazolam   250 micrograms  
 Clobazam  10 mg  
 Clonazepam  250 micrograms 
 Flurazepam  7.5 – 15 mg 
 Chlordiazepoxide  12.5 mg 
 Loprazolam  0.5 – 1 mg 
 Lorazepam  500 micrograms 
 Lormetazepam  0.5 – 1.0 mg 
 Nitrazepam  5 mg 
 Oxazepam  10 mg 
 Temazepam  10 mg 
 Zaleplon  10 mg 
 Zolpidem  10 mg 








Supplementary Material 2 
 
Plots for all individual drugs analysed, using data from England, 2017. For each drug is shown: (1) 
mean prescribing per 1000 patients (with 95% confidence intervals), for GP practices within each 
index of multiple deprivation (IMD) decile; (2) choropleth maps of prescribing deciles by Clinical 
Commissioning Group region (CCG), alongside a map of IMD deciles by CCG; and (3) bivariate 






Average prescribing by practice Index of Multiple 
Deprivation (IMD) decile (England, 2017): 
Index of Multiple Deprivation decile 
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Chlordiazepoxide prescribing and Index of Multiple Deprivation score by                   






Average prescribing by practice Index of Multiple 
Deprivation (IMD) decile (England, 2017): 
Index of Multiple Deprivation decile 
Index of Multiple Deprivation scores 
by Clinical Commissioning Group 
Clobazam prescribing by                







Clobazam prescribing and Index of Multiple Deprivation score by                   


















Figure C.3: Geographical heat map of England combining the level of Clonazepam prescribing and 
the level of deprivation 
 
Average prescribing by practice Index of Multiple 
Deprivation (IMD) decile (England, 2017): 
Index of Multiple Deprivation decile 
Index of Multiple Deprivation scores 
by Clinical Commissioning Group 
Clonazepam prescribing by             








Clonazepam prescribing and Index of Multiple Deprivation score by                   



















Average prescribing by practice Index of Multiple 
Deprivation (IMD) decile (England, 2017): 
Index of Multiple Deprivation decile 
Index of Multiple Deprivation scores 
by Clinical Commissioning Group 
Diazepam prescribing by                







Diazepam prescribing and Index of Multiple Deprivation score by                   














Average prescribing by practice Index of Multiple 
Deprivation (IMD) decile (England, 2017): 
Index of Multiple Deprivation decile 
Index of Multiple Deprivation scores 
by Clinical Commissioning Group 
Lorazepam prescribing by                 







Lorazepam prescribing and Index of Multiple Deprivation score by                   















Average prescribing by practice Index of Multiple 
Deprivation (IMD) decile (England, 2017): 
Index of Multiple Deprivation decile 
Index of Multiple Deprivation scores 
by Clinical Commissioning Group 
Nitrazepam prescribing by            






Nitrazepam prescribing and Index of Multiple Deprivation score by                   









Average prescribing by practice Index of Multiple 
Deprivation (IMD) decile (England, 2017): 
Index of Multiple Deprivation decile 
Index of Multiple Deprivation scores 
by Clinical Commissioning Group 
Temazepam prescribing by                 






Temazepam prescribing and Index of Multiple Deprivation score by                   







Average prescribing by practice Index of Multiple 
Deprivation (IMD) decile (England, 2017): 
Index of Multiple Deprivation decile 
Index of Multiple Deprivation scores 
by Clinical Commissioning Group 
Zopiclone prescribing by                   












Zopiclone prescribing and Index of Multiple Deprivation score by                   
Clinical Commissioning Group 
